[1] SANDLER A,GRAY R,PERRY M C,et al. Paclitaxelcarboplatinalone or with bevacizumab for non-small-cell lung cancer[J]. N Engl J Med, 2006, 355(24):2542-2550. [2] MARTINEZ-LOSTAO L, BRIONES J, MARTINEZGALLO M, et al. Fludarabine-induced apoptosis in CD19+/CD5+ B- CLL cells is a direct and nurse-like-cell independent effect[J]. Leuk Lymphoma, 2004, 45(11):2307-2314. [3] JIANG L,HAO J L,JIN M L,et al. Effect of Embelin on TRAIL receptor 2 mAb-induced apoptosis of TRAILresistant A549 non-small cell lung cancer cells[J]. Asian Pac J Cancer Prev,2013,14:6115-6120. [4] MAHALINGAM D, SZEGEZDI E, KEANE M, et al. TRAIL receptor signalling and modulation:Are we on the right TRAIL[J]. Cancer Treat Rev,2009,35(3):280-288. [5] MADURO J H,NOORDHUIS M G,TENHOOR K A,et al. The prognostic value of TRAIL and its death receptors in cervical cancer[J]. Int J Radiat Oncol Biol Phys, 2009,75(1):203-211. [6] ZHANG L,FANG B. Mechanisms of resistance to TRAILinduced apoptosis in cancer[J]. Cancer Gene Ther,2005, 12:228-237. [7] HENRY C M,MARTIN S J. Caspase-8 acts in a nonenzymatic role as a scaffold for assembly of a proinflammatory"FADDosome"complex upon TRAIL stimulation[J]. Mol Cell,2017,65(4):715-729. [8] GARG H, SURI P, GUPTA J C, et al. Survivin:a unique target for tumor therapy[J]. Cancer Cell Int, 2016,16(49):1-14. [9] LIN F L, HSU J L, CHOU C H, et al. Activation of p38 MAPK by damnacanthal mediates apoptosis in SKHep1 cells through the DR5/TRAIL and TNFR1/TNF-α and p53 pathways[J]. Eur J Pharmacol, 2011, 650:120-129. [10] VALIZADEH A, AHMADZADEH A, SAKI G, et al. Role of tumor necrosis factor-producing mesenchymal stem cells on apoptosis of chronic B-lymphocytic tumor cells resistant to Fludarabine-based chemotherapy[J]. Asian Pac J Cancer Prev,2015,16(18):8533-8539. |